Publications

Poster Presentation Approval / Commercialization Care Gastroenterology

Characterization and Impact of Risankizumab on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.

Characterization and Impact of Risankizumab on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO

Poster Presentation Approval / Commercialization Care Gastroenterology

Characterization and Impact of Upadacitinib on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.

Characterization and Impact of Upadacitinib on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO

Poster Presentation R&D Care Gastroenterology

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Crohn's Disease: Findings From TARGET-IBD.

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Crohn's Disease: Findings From TARGET-IBD

Poster Presentation R&D Care Gastroenterology

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Ulcerative Colitis: Findings From TARGET-IBD.

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Ulcerative Colitis: Findings From TARGET-IBD

Poster Presentation R&D Care Gastroenterology

Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort.

Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort

Total Publications

Abstract / Manuscript

Oral Presentation

Poster Presentation

2026 · Poster Presentation · Poster Presentation · Gastroenterology

Characterization and Impact of Risankizumab on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.

2026 · Poster Presentation · Poster Presentation · Gastroenterology

Characterization and Impact of Upadacitinib on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.

2026 · Poster Presentation · Poster Presentation · Gastroenterology

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Crohn's Disease: Findings From TARGET-IBD.

2026 · Poster Presentation · Poster Presentation · Gastroenterology

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Ulcerative Colitis: Findings From TARGET-IBD.

2024 · Poster Presentation · Poster Presentation · Gastroenterology

Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort.

2024 · Poster Presentation · Poster Presentation · Gastroenterology

Time to Diagnosis Among Patients with Eosinophilic Esophagitis in the United States.

2024 · Abstract / Manuscript · Abstract / Manuscript

Factors Predicting Loss of Remission in Crohn’s Disease Patients in Endoscopic Remission in the Real World Results From TARGET-IBD.

2023 · Poster Presentation · Poster Presentation · Gastroenterology

Outcomes of early vs. delayed advanced therapy among patients with moderate ulcerative colitis in the United States: TARGET-IBD.

2023 · Poster Presentation · Poster Presentation · Gastroenterology

Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis.

2022 · Abstract / Manuscript · Abstract / Manuscript

Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET‑IBD.

2021 · Poster Presentation · Poster Presentation · Gastroenterology

Histological Inflammation Predicts Loss of Remission Among Crohn’s Patients with Endoscopic Remission: A US Cohort Analysis.

2021 · Poster Presentation · Poster Presentation · Gastroenterology

Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort.

2021 · Poster Presentation · Poster Presentation · Gastroenterology

Biologic-naïve Patients with Crohn’s Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort.

2021 · Abstract / Manuscript · Abstract / Manuscript

Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease.

2021 · Abstract / Manuscript · Abstract / Manuscript

Methodology and initial results from a real-world observational cohort of patients with inflammatory bowel disease: TARGET-IBD.

2020 · Poster Presentation · Poster Presentation · Gastroenterology

Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.

2020 · Oral Presentation · Oral Presentation · Gastroenterology

Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD.

2020 · Poster Presentation · Care · Gastroenterology

Oral Mesalamine Use in Crohn’s Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study.

2019 · Poster Presentation · Care · Gastroenterology

Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study.

2018 · Poster Presentation · Poster Presentation · Gastroenterology

Publications

Characterization and Impact of Risankizumab on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.

Characterization and Impact of Upadacitinib on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Crohn's Disease: Findings From TARGET-IBD.

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Ulcerative Colitis: Findings From TARGET-IBD.

Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort.

Characterization and Impact of Risankizumab on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.

Characterization and Impact of Upadacitinib on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Crohn's Disease: Findings From TARGET-IBD.

Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Ulcerative Colitis: Findings From TARGET-IBD.

Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort.

Time to Diagnosis Among Patients with Eosinophilic Esophagitis in the United States.

Factors Predicting Loss of Remission in Crohn’s Disease Patients in Endoscopic Remission in the Real World Results From TARGET-IBD.

Outcomes of early vs. delayed advanced therapy among patients with moderate ulcerative colitis in the United States: TARGET-IBD.

Treatment Journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD.

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease.

The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn’s Disease in TARGET IBD.

Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD.

Inflammation on Index Biopsy Predicts Loss of Remission Among Ulcerative Colitis Patients with Endoscopic Remission: a US Cohort Analysis.

Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET‑IBD.

Histological Inflammation Predicts Loss of Remission Among Crohn’s Patients with Endoscopic Remission: A US Cohort Analysis.

Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort.

Biologic-naïve Patients with Crohn’s Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort.

Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease.

Methodology and initial results from a real-world observational cohort of patients with inflammatory bowel disease: TARGET-IBD.

Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.

Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD.

Oral Mesalamine Use in Crohn’s Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study.

Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study.

Development of a Novel Longitudinal Observational Cohort of Adult and Pediatric Patients with Inflammatory Bowel Disease: TARGET-IBD.